EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 164 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $455,359 | +47984.4% | 28,875 | -10.8% | 0.01% | -73.7% |
Q4 2022 | $947 | -99.9% | 32,382 | +17.9% | 0.02% | +18.8% |
Q3 2022 | $726,000 | -28.3% | 27,461 | +20.5% | 0.02% | -40.7% |
Q2 2022 | $1,013,000 | +127.1% | 22,793 | +207.0% | 0.03% | +35.0% |
Q4 2019 | $446,000 | -62.0% | 7,425 | -64.3% | 0.02% | -50.0% |
Q3 2019 | $1,175,000 | +113.2% | 20,778 | +109.8% | 0.04% | +150.0% |
Q2 2019 | $551,000 | -8.0% | 9,903 | -16.6% | 0.02% | -36.0% |
Q1 2019 | $599,000 | -30.0% | 11,870 | -44.1% | 0.02% | +47.1% |
Q4 2018 | $856,000 | -1.8% | 21,244 | +68.9% | 0.02% | -22.7% |
Q3 2018 | $872,000 | +185.9% | 12,577 | +211.9% | 0.02% | +100.0% |
Q2 2018 | $305,000 | +12.1% | 4,033 | -42.4% | 0.01% | +83.3% |
Q2 2016 | $272,000 | +24.2% | 7,000 | +29.6% | 0.01% | 0.0% |
Q1 2016 | $219,000 | -61.8% | 5,400 | -16.5% | 0.01% | -62.5% |
Q4 2015 | $573,000 | – | 6,467 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 121,014 | $5,377,000 | 1.78% |
Smith, Graham & Co., Investment Advisors, LP | 232,343 | $10,323,000 | 1.28% |
GLOBEFLEX CAPITAL L P | 73,205 | $3,252,000 | 0.79% |
SummerHaven Investment Management, LLC | 18,604 | $827,000 | 0.56% |
BRANDES INVESTMENT PARTNERS, LP | 464,292 | $20,628,000 | 0.50% |
Capital Impact Advisors, LLC | 11,728 | $521,000 | 0.48% |
Watershed Asset Management, L.L.C. | 5,756 | $256,000 | 0.32% |
Foundry Partners, LLC | 84,325 | $3,747,000 | 0.23% |
Summit Global Investments | 33,738 | $1,499,000 | 0.13% |
SCOUT INVESTMENTS, INC. | 147,034 | $6,533,000 | 0.13% |